- Home
- SPB vs IBRX Comparison
SPB vs IBRX Comparison
Compare SPB & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPB
- IBRX
- Stock Information
- Founded
- SPB 1906
- IBRX 2014
- Country
- SPB United States
- IBRX United States
- Employees
- SPB N/A
- IBRX N/A
- Industry
- SPB Industrial Machinery/Components
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPB Miscellaneous
- IBRX Health Care
- Exchange
- SPB Nasdaq
- IBRX Nasdaq
- Market Cap
- SPB 2.5B
- IBRX 2.4B
- IPO Year
- SPB N/A
- IBRX N/A
- Fundamental
- Price
- SPB $90.26
- IBRX $5.04
- Analyst Decision
- SPB Buy
- IBRX Buy
- Analyst Count
- SPB 7
- IBRX 2
- Target Price
- SPB $101.71
- IBRX $17.38
- AVG Volume (30 Days)
- SPB 327.5K
- IBRX 10.2M
- Earning Date
- SPB 11-15-2024
- IBRX 11-12-2024
- Dividend Yield
- SPB 1.88%
- IBRX N/A
- EPS Growth
- SPB N/A
- IBRX N/A
- EPS
- SPB 4.10
- IBRX N/A
- Revenue
- SPB $2,963,900,000.00
- IBRX $7,332,000.00
- Revenue This Year
- SPB $1.96
- IBRX $1,563.18
- Revenue Next Year
- SPB $1.85
- IBRX $1,262.20
- P/E Ratio
- SPB $21.87
- IBRX N/A
- Revenue Growth
- SPB 1.55
- IBRX 1218.71
- 52 Week Low
- SPB $65.50
- IBRX $3.10
- 52 Week High
- SPB $96.74
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- SPB 47.32
- IBRX 53.24
- Support Level
- SPB $85.44
- IBRX $4.80
- Resistance Level
- SPB $91.45
- IBRX $5.38
- Average True Range (ATR)
- SPB 2.53
- IBRX 0.49
- MACD
- SPB -0.27
- IBRX -0.08
- Stochastic Oscillator
- SPB 47.07
- IBRX 41.72
About SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.